<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00298298</url>
  </required_header>
  <id_info>
    <org_study_id>A/100/0601</org_study_id>
    <nct_id>NCT00298298</nct_id>
  </id_info>
  <brief_title>DNP-Modified Autologous Tumor Cell Vaccine for Resectable Non-Small Cell Lung Cancer</brief_title>
  <official_title>L-Vax: A Feasibility Study Using a DNP-Modified Autologous Tumor Cell Vaccine as Therapy in Patients With Resectable Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AVAX Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AVAX Technologies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if a vaccine made from patient's own tumor tissue can stimulate an immune&#xD;
      response against the patient's tumor cells. To determine the safety of the vaccine&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Objectives: To study the toxicity, safety and delayed-type hypersensitivity (DTH)&#xD;
      responses of DNP-modified autologous tumor cell vaccine (L-Vax) in patients with resectable&#xD;
      NSCLC:&#xD;
&#xD;
        -  To determine the tolerability and toxicity of L-Vax&#xD;
&#xD;
        -  To determine whether L-Vax induces a DTH response to autologous, DNP-modified NSCLC&#xD;
           cells of similar magnitude to responses observed with melanoma&#xD;
&#xD;
        -  Determine whether L-Vax induces a DTH response to autologous unmodified NSCLC cells&#xD;
&#xD;
        -  To determine whether the DTH responses to autologous, unmodified NSCLC cells that have&#xD;
           been fixed with ethanol correlate with DTH responses to autologous, unmodified NSCLC&#xD;
           cells that are not fixed&#xD;
&#xD;
      Study Population: Patients with resectable NSCLC whose therapeutic tumor surgery provides a&#xD;
      mass, which yields adequate tumor, cells for vaccine preparation and DTH testing&#xD;
&#xD;
      Study Design: A Phase I/IIa double-blind, three-dose, single center study&#xD;
&#xD;
      Investigational Product: L-Vax: DNP-modified autologous NSCLC cell vaccine&#xD;
&#xD;
      Dosage Form: Cell suspension&#xD;
&#xD;
      Route of Administration: Intradermal&#xD;
&#xD;
      Dosage and Treatment Schedule: Prior to vaccine administration, patients will be tested for&#xD;
      DTH to autologous NSCLC cells that have been: DNP-modified, or unmodified and irradiated, or&#xD;
      unmodified and irradiated and fixed with ethanol (if sufficient cells available) Three doses&#xD;
      of vaccine will be tested: 5 x 105, 2.5 x 106, or 5 x 106 DNP-modified autologous NSCLC&#xD;
      cells. An initial dose of DNP-modified autologous NSCLC cells* without Bacillus of Calmette&#xD;
      and Guérin (BCG) followed by cyclophosphamide (CY) then weekly doses of DNP-modified&#xD;
      autologous NSCLC tumor cells mixed with BCG for 6 weeks, and completed with one dose of&#xD;
      DNP-modified autologous NSCLC tumor cells mixed with BCG as a 6-month booster, if adequate&#xD;
      number of cells available.&#xD;
&#xD;
        -  count determined prior to aliquoting for cryopreservation&#xD;
&#xD;
      Endpoints: Treatment-emergent and related adverse events, serious adverse events, and Grade 3&#xD;
      and 4 laboratory abnormalities for safety assessments&#xD;
&#xD;
      Other Parameters: · DTH skin reactions for assessing the induction of immune responses to&#xD;
      DNP-modified and unmodified autologous NSCLC tumor cells· Survival· Exploratory analysis of&#xD;
      in vitro studies of peripheral blood lymphocytes obtained from study subjects&#xD;
&#xD;
      Duration of Treatment: Up to 9 months&#xD;
&#xD;
      Duration of Subject Participation in Study: Three months from the patient's last vaccine&#xD;
&#xD;
      Duration of Follow-up: Survival information and disease status will be collected via phone or&#xD;
      visit on a quarterly basis for each patient beginning 30 days after the last scheduled visit&#xD;
      until the last patient has been followed for three months from his/her last vaccine&#xD;
&#xD;
      Number of Subjects Required to Meet Protocol Objectives: Up to 42 evaluable subjects&#xD;
&#xD;
      Number of Study Centers: Three&#xD;
&#xD;
      Number of Individual Blood Draws: 15 draws over nine months&#xD;
&#xD;
      Volume of Blood Drawn: 13 Draws of 30 mL/draw (total 360 mL) and two draws of 50mL in&#xD;
      heparinized tubes&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Suspended until capitalization is completed&#xD;
  </why_stopped>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cell-mediated immunity to autologous tumor cells.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Non-Small Cell Lung Cancer - Completely Resectable</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 million autologous, DNP-modified NSCLC cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5 million autologous, DNP-modified NSCLC cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 million autologous, DNP-modified NSCLC cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>L-Vax: Autologous, DNP-Modified NSCLC Vaccine</intervention_name>
    <description>autologous, DNP-modified NSCLC cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically documented stage IA, IB, IIA, IIB or IIIA NSCLC that is completely&#xD;
             resectable and does not require post-operative radiation therapy or peri-operative&#xD;
             chemotherapy&#xD;
&#xD;
          -  Excision of the tumor and harvesting of tumor mass yielding adequate cells for vaccine&#xD;
             manufacture and DTH testing&#xD;
&#xD;
          -  Successful preparation and lot release of vaccines and of DTH testing material&#xD;
             containing DNP-modified tumor cells&#xD;
&#xD;
          -  Minimum of 3 and maximum of 8 weeks since the surgery&#xD;
&#xD;
          -  Expected survival of at least 6 months&#xD;
&#xD;
          -  Karnofsky performance status ³ 80&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Alkaline phosphatase &gt; 2.5 x ULN&#xD;
&#xD;
          -  Total bilirubin &gt; 2.0 mg/dL&#xD;
&#xD;
          -  Creatinine &gt; 2.0 mg/dL&#xD;
&#xD;
          -  Hemoglobin &lt; 10.0 g/dL&#xD;
&#xD;
          -  WBC &lt; 3,000 /mm3&#xD;
&#xD;
          -  Platelet count &lt; 100,000/mm3&#xD;
&#xD;
          -  Chemotherapy - pre-operative or post-operative (except as designated in protocol)&#xD;
&#xD;
          -  Radiation therapy to lung - pre-operative or post-operative&#xD;
&#xD;
          -  Any major field radiotherapy within 6 months prior to participation in the study&#xD;
&#xD;
          -  Immunotherapy (interferons, tumor necrosis factor, other cytokines [e.g.,&#xD;
             interleukins], biological response modifiers, or monoclonal antibodies) within 4 weeks&#xD;
             prior to participation in the study&#xD;
&#xD;
          -  Prior splenectomy&#xD;
&#xD;
          -  Concurrent use of systemic steroids, except for the period of administration of the&#xD;
             adjuvant chemotherapy, as per Section 8.6 (months 4-7)(Note: Topical steroid therapies&#xD;
             [applied to the skin] are allowed, provided these are not applied to limbs injected&#xD;
             with vaccine or skin test materials. Inhaled aerosol steroids are allowed.)&#xD;
&#xD;
          -  Concurrent use of immunosuppressive drugs, except for the period of administration of&#xD;
             the adjuvant chemotherapy (months 4-7)&#xD;
&#xD;
          -  Concurrent use of antitubercular drugs (isoniazid, rifampin, streptomycin)&#xD;
&#xD;
          -  Other malignancy within 5 years except curatively treated non-melanomatous skin cancer&#xD;
             and curatively treated carcinoma in situ of the uterine cervix, or early stage (stage&#xD;
             A or B1) prostate cancer&#xD;
&#xD;
          -  Concurrent autoimmune diseases, e.g., systemic lupus erythematosus, multiple sclerosis&#xD;
             or ankylosing spondylitis&#xD;
&#xD;
          -  Concurrent medical condition that would preclude compliance or immunologic response to&#xD;
             study treatment&#xD;
&#xD;
          -  Concurrent serious infection or other serious medical condition&#xD;
&#xD;
          -  Receipt of any investigational medication within 4 weeks prior to participation in the&#xD;
             study&#xD;
&#xD;
          -  Pregnancy or lactation (serum b-human chorionic gonadotropin [b-HCG] test must be&#xD;
             negative in fertile women at screening visit)&#xD;
&#xD;
          -  Active tuberculosis or a past history of tuberculosis&#xD;
&#xD;
          -  PPD positive (³ 5 mm to 5TU)&#xD;
&#xD;
          -  Known gentamicin sensitivity&#xD;
&#xD;
          -  Anergic, defined by the inability to make a DTH to at least one of the following:&#xD;
             candida, mumps, tetanus or trichophyton (based, except for the period of&#xD;
             administration of the adjuvant chemotherapy (months 4-7) upon availability)&#xD;
&#xD;
          -  Vaccine lot release failure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry E Schea</last_name>
    <role>Study Director</role>
    <affiliation>AVAX Technologies</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Berd D, Sato T, Cohn H, Maguire HC Jr, Mastrangelo MJ. Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases. Int J Cancer. 2001 Nov;94(4):531-9.</citation>
    <PMID>11745440</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>February 28, 2006</study_first_submitted>
  <study_first_submitted_qc>March 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2006</study_first_posted>
  <last_update_submitted>December 2, 2015</last_update_submitted>
  <last_update_submitted_qc>December 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lung cancer</keyword>
  <keyword>non-small cell lung cancere</keyword>
  <keyword>vaccine</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

